CTOs on the Move

Civica Rx

www.civicarx.org

 
Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.civicarx.org
  • 2912 Executive Parkway
    Lehi, UT USA 84043
  • Phone: 888.304.0120

Executives

Name Title Contact Details

Similar Companies

SiO2

SiO2 is a Auburn, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Norwich Pharmaceuticals

Norwich Pharmaceuticals, Inc. is a Norwich, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unisource NTC

Unisource NTC is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prometheus Laboratories

Prometheus Laboratories Inc. is one of the leading companies in the Healthcare, Pharmaceuticals and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.